Stage IA-IIB hodgkin's disease: Management and outcome of extensive thoracic involvement

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 2 SUPPL., 1997, Pages 361-369

  Hughes Davies, Luke ^a   Tarbell, Nancy J ^a   Coleman, C Norman ^a   Silver, Barbara ^a   Shulman, Lawrence N ^a   Linggood, Rita ^a   Canellos, George P ^b,c   Mauch, Peter M ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

Combined chemotherapy and radiation therapy; Hodgkin's disease; Large mediastinal involvement; Stage I II

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; HEART INFARCTION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEDIASTINUM CANCER; MULTIMODALITY CANCER THERAPY; PNEUMONIA; PRIORITY JOURNAL; RISK; SECOND CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; MEDIASTINAL NEOPLASMS; NEOPLASM STAGING; RADIATION PNEUMONITIS; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0030865951     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00085-0     Document Type: Article

References (48)

1. Behar, R.; Hoppe, R. Radiation therapy in the management of bulky mediastinal Hodgkin's disease. Cancer 66:75-79; 1990.
2. Behar, R.; Horning, S.; Hoppe, R. Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 25:771-776; 1993.
3. Biti, G.; Cellai, E.; Magrini, S.; Papi, M.; Ponticelli, P.; Boddi, V. Second solid tumors and leukemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. Int. J. Radiat. Oncol. Biol. Phys. 29:25-31; 1994.
4. Boivin, J.-F.; Hutchison, G.; Lubin, J.; Mauch, P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241-1247; 1992.
5. Bonadonna, G; Santoro, A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat. Rev. 9:21; 1982.
6. Brizel, D.; Winer, E.; Prosnitz, L.; Scott, J.; Crawford, J.; Moore, J.; Grockerman, J. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 19:535-542; 1991.
7. Brosius, F. I.; Waller, B.; Roberts, W. Radiation heart disease. Am. J. Med. 70:519-530; 1981.
8. Castellino, R.; Glatstein, E.; Turbow, M.; Rosenberg, S.; Kaplan, H. S. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann. Intern. Med. 80:593-599; 1974.
9. Cosset, J.; Henry-Amar, M.; Pellae-Cosset, B. Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int. J. Radiat. Oncol. Biol. Phys. 21:447-449; 1991.
10. Crnkovich, M.; Leopold, K.; Hoppe, R.; Mauch, P. Stage I to IIB Hodgkin's disease: The combined experience at Stanford University and the Joint Center for Radiation Therapy. J. Clin. Oncol. 5:1041-1049; 1987.
11. DeVita, V.; Serpick, A.; Carbone, P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 73:881-895; 1970.
12. Donaldson, S.; Link, M. Combined modality treatment with low dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J. Clin. Oncol. 5:742-749; 1987.
13. Dowling, S.; Peschel, R.; Portlock, C.; Kramer, C.; Farber, L.; Knowlton, A. Mediastinal irradiation in combined modality for Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 19:543-546; 1990.
14. Duhmke, E.; Diehl, V.; Loeffler, M.; Mueller, R.-P.; Ruehl, U.; Willich, N.; Georgii, A.; Roth, S.; Matthaei, D.; Shelen, S.; Brosteanu, O.; Hasenclever, D.; Wilkowski, R.; Becker, K. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int. J. Radiat. Oncol. Biol. Phys. 36:305-310; 1996.
15. Fuller, L.; Madoc-Jones, H.; Shullenberger, C.; Hagemeister, F.; Martin, R.; Gamble, J.; Rogers, R.; North, L.; Butler, J. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: Significance of mediastinal and non-mediastinal presentations. Int. J. Radiat. Oncol. Biol. Phys. 6:799-808; 1980.
16. Gospodarowicz, M.; Sutcliffe, S.; Clark, R.; Dembo, A.; Fitzpatrick, P.; Tsang, R.; Chua, T.; Bush, R. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int. J. Radiat. Oncol. Biol. Phys. 22:859-865; 1992.
17. Gottdiener, J.; Katin, M.; Borer, J.; Bacharach, S.; Green, M. Late cardiac effects of therapeutic mediastinal irradiation. N. Engl. J. Med. 308:569-588; 1983.
18. Hancock, S.; Donaldson, S.; Hoppe, R. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J. Clin. Oncol. 11:1208-1215; 1993.
19. Harker, W.; Kushlan, P.; Rosenberg, S. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann. Intern. Med. 101:440-446; 1984.
20. Healey, E.; Tarbell, N.; Kalish, L.; Silver, B.; Rosenthal, D.; Marcus, K.; Shulman, L.; Coleman, C.; Canellos, G.; Weinstein, H.; Mauch, P. Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 71:2613-2620; 1993.
21. Hoppe, R. The management of stage II Hodgkin's disease with a large mediastinal mass: A prospective program emphasizing irradiation. Int. J. Radiat. Oncol. Biol. Phys. 11:349-355; 1985.
22. Hoppe, R.; Coleman, C.; Cox, R.; Rosenberg, S.; Kaplan, H. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 59:455-465; 1982.
23. Hoppe, R.; Coleman, C.; Kaplan, H. Hodgkin's disease, pathological stage I and II, the prognostic importance of initial sites of disease and extent of mediastinal involvement. Proc. Am. Soc. Clin. Oncol. 21:471; 1980.
24. Kaplan, E; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481; 1958.
25. Lee, C.; Bloomfield, C.; Goldman, A.; Levitt, S. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46:2403-2409; 1980.
26. Lee, C.; Bloomfield, C.; Goldman, A.; Nesbit, M.; Levitt, S. The therapeutic utility of lung irradiation for Hodgkin's disease patients with large mediastinal. Int. J. Radiat. Oncol. Biol. Phys. 7:151-154; 1981.
27. Lee, C.; Bloomfield, C.; Levitt, S. Results of lung irradiation for Hodgkin's disease patients with large mediastinal masses and/or hilar disease. Cancer. Treat. Rep. 66:819-825; 1982.
28. Leopold, K.; Canellos, G.; Rosenthal, D.; Shulman, L.; Weinstein, H.; Mauch, P. Stage IA-IIB Hodgkin's disease: Staging and treatment of patients with large mediastinal adenopathy. J. Clin. Oncol. 7:1059-1065; 1989.
29. Lister, T.; Crowther, D.; Sutcliffe, S.; Glatstein, E.; Canellos, G.; Young, R.; Rosenberg, S.; Coltman, C.; Tubiana, M. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J. Clin. Oncol. 7:1630-1636; 1989.
30. Longo, D.; Russo, A.; Duffey, P.; Hubbard, S.; Glatstein, E.; Hill, J.; Jaffe, E.; Young, R.; DeVita, V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J. Clin. Oncol. 9:227-235;1991.
31. Mauch, P. Controversies in the management of patients with early stage Hodgkin's disease. Blood 83:318-329; 1994.
32. Mauch, P.; Goodman, R.; Hellman, S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039-1045; 1978.
33. Mauch, P.; Gorshein, D.; Cunningham, J.; Hellman, S. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. Cancer Treat. Rep. 66:809-817; 1982.
34. Mauch, P.; Hellman, S. Supradiaphragmatic Hodgkin's disease: Is there a role for MOPP chemotherapy in patients with bulky mediastinal disease? Int. J. Radiat. Oncol. Biol. Phys. 6:947-949; 1980.
35. Mauch, P.; Kalish, L.; Marcus, K.; Shulman, L.; Krill, E.; Tarbell, N.; Silver, B.; Weinstein, H.; Come, S.; Canellos, G.; Coleman, C. Long-term survival in Hodgkin's disease: Relative impact of mortality, infection, second tumors, and cardiovascular disease. Cancer J. Sci. Am. 1:33-42; 1995.
36. Mauch, P.; Tarbell, N.; Weinstein, H.; Silver, B.; Goffman, T.; Osteen, R.; Zajac, A.; Coleman, C.; Canellos, G.; Rosenthal, D. Stage IA and IIA supradiaphragmatic Hodgkin's Disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J. Clin. Oncol. 6:1576-1583; 1988.
37. McKendrick, J.; Mead, G.; Sweetenham, J.; Jones, D.; Williams, C.; Ryall, R.; Whitehouse, J. ChlVPP chemotherapy in advanced Hodgkin's disease. Eur. J. Cancer Clin. Oncol. 25:557-561; 1989.
38. Pavlovsky, S.; Maschio, M.; Santarelli, M.; Muriel, F.; Corrado, C.; Garcia, I.; Schwartz, L.; Montero, C.; Sanahuja, F.; Magnasco, O.; Rana, R.; Cavagnaro, F. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J. Natl. Cancer Instit. 80:1466-1473; 1988.
39. Perrault, D.; Levy, M.; Herman, J.; Burns, R.; Bar Shlomo, B.-Z.; Druck, M.; Wu, W.; McLaughlin, P.; Gilbert, B. Echocardiographic abnormalities following cardiac radiation. J. Clin. Oncol. 3:546-551; 1985.
40. Prosnitz, L.; Curtis, A.; Knowlton, A.; Peters, L.; Farber, L. Supradiaphragmatic Hodgkin's disease: Significance of large mediastinal masses. Int. J. Radiat. Oncol. Biol. Phys. 6:809-813; 1980.
41. Radford, J.; Cowan, R.; Flanagan, M.; Dunn, G.; Crowther, D.; Johnson, R.; Eddleston, B. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J. Clin. Oncol. 6:940-946; 1988.
42. Santoro, A.; Bonfante, V.; Bonadonna, G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann. Intern. Med. 96:139-143; 1982.
43. Schomberg, P.; Evans, R.; O'Connell, M. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46:2403-2409; 1980.
44. Schomberg, P.; Evans, R.; O'Connell, M.; White, W.; Banks, P.; Ilstrup, D.; Earle, J. Prognostic significance of mediastinal mass in adult Hodgkin's disease. Cancer 53:324-328; 1984.
45. Specht, L.; Nordentoft, A.; Cold, S.; Clausen, N.; Nissen, N. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61:1719-1727; 1988.
46. Tarbell, N.; Gelber, R.; Weinstein, H.; Mauch, P. Sex differences in risk of second malignant tumours after Hodgkin's disease. Lancet 341:1428-1432; 1993.
47. Tarbell, N.; Thompson, L.; Mauch, P. Thoracic irradiation in Hodgkin's disease: Disease control and long-term complications. Int. J. Radiat. Oncol. Biol. Phys. 18:275-281; 1990.
48. Tubiana, M.; Henry-Amar, M.; Carde, P.; Burgers, J.; Hayat, M.; Van der Schueren, E.; Noordijk, E.; Tanguy, A.; Meerwaldt, J.; Thomas, J.; De Pauw, B.; Monconduit, M.; Cosset, J.; Somers, R. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73:47-56; 1989.